Aim To examine the effect of probucol on major advanced cardiovascular events (MACE) in patients with coronary artery disease undergone PCI. Methods Electronic databases, including PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trial, CNKI database and Wan-Fang Database were used. The search items of“antioxidant”or“probucol” or “vitamin C”or “vitamin E” or “N-acetylcysteine”and “angioplasty”or “stent” and “randomized” were selected. RevMan 5.3 provided by the Cochrane was used to perform this analysis. Results In the enrolled 349 articles, there were 7 articles reporting MACE events in patients with coronary heart disease undergone PCI. There were 72 events in antioxidant group (72/2,0.5%). 111 events occurred in control group (111/4,1.4%). Compared to control group, antioxidant (probucol) group significantly decreased the incidence of MACE (RR 0.5,5%CI 0.51~0.84, P=0.0008). Compared with control group (86/2,4.3%), there was a lower rate of repeat revascularization in antioxidant group (52/2,4.8; RR 0.1,5%CI 0.44~0.83, P=0.002). No difference was observed in myocardial infarction death between groups (P=0.34,P=0.49). In addition, total cholesterol (TC) and low density lipoprotein- cholesterol (LDLC) were significantly decreased in probucol group when compared with control group (standard mean reduction SMD －0.8,5%CI －0.87~－0.49, P<0.00001; SMD －0.8,5%CI －0.46~－0.11, P=0.001, respectively). Conclusions Antioxidant probucol combined with conventional treatment significantly decreased the rate of MACE in patients with coronary artery disease undergone PCI. This benefit may be related to the improvement of repeat revascularization and lipid profile.